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Objective. )e purpose of this study was to describe baseline data on etiological, clinical, laboratory, and management strategies in
Kenyan children and adolescents with Disorders of Sex Development (DSD).Methods. )is retrospective study included patients
diagnosed with DSD who presented at ages 0–19 years from January 2008 to December 2015 at the Kenyatta National (KNH) and
Gertrude’s Children’s (GCH) Hospitals. After conducting a search in the data registry, a structured data collection sheet was used
for collection of demographic and clinical data. Data analysis involved description of the frequency of occurrence of various
variables, such as etiologic diagnoses and patient characteristics. Results. Data from the records of 71 children and adolescents
were reviewed at KNH (n� 57, 80.3%) and GCH (n� 14, 19.7%).)emean age at the time of diagnosis was 2.7 years with amedian
of 3 months.)irty-nine (54.9%) children had karyotype testing done.)emedian age (IQR) of children with reported karyotypes
and those without was 3.3 years (1.3–8.9) and 8.3 years (3.6–12.1), respectively (p � 0.021). Based on karyotype analysis, 19
(48.7%) of karyotyped children had 46,XY DSD and 18 (46.2%) had 46,XX DSD. )ere were two (5.1%) children with sex
chromosome DSD. Among the 71 patients, the most common presumed causes of DSD were ovotesticular DSD (14.1%) and CAH
(11.3%). Majority (95.7%) of the patients presented with symptoms of DSD at birth. )e most common presenting symptom was
ambiguous genitalia, which was present in 66 (93.0%) patients either in isolation or in association with other symptoms. An
ambiguous genitalia was initially observed by the patient’s mother in 51.6% of 62 cases despite the high rate (84.7%) of delivery in
hospital. Seventeen (23.9%) of the cases had a gender reassignment at ﬁnal diagnosis. A psychologist/psychiatrist or counselor was
involved in the management of 23.9% of the patients. Conclusion. )e commonest presumed cause of DSD was ovotesticular DSD
in contrast to western studies, which found CAH to be more common. Investigation of DSD cases is expensive and needs to be
supported. We would have liked to do molecular genetic analysis outside the country but ﬁnancial challenges made it impossible.
A network for detailed diagnostics in resource-limited countries would be highly desirable. )ere is a need to train health care
workers and medical students for early diagnosis. Psychological evaluation should be carried out for all patients at diagnosis and
support given for families.
1. Introduction
Disorders of Sex Development (DSD) are congenital condi-
tions with atypical development of chromosomal, gonadal, or
anatomical sex [1].)e classiﬁcation of ambiguous genitalia in
patients is diﬃcult because similar phenotypes may have
several etiologies [2–6]. In 2006, Lawson Wilkins Pediatric
Endocrine Society (LWPES) and European Society for Pae-
diatric Endocrinology (ESPE) proposed a classiﬁcation system
for causes of intersex disorders on the basis of karyotype
analysis [4]. )is classiﬁcation includes three diagnostic cat-
egories: sex chromosome DSD, 46,XY DSD (formerly male
pseudohermaphroditism) and 46,XX DSD (formerly female
pseudohermaphroditism).
)ere is a paucity of data on the incidence of DSD; it is
estimated that the overall incidence of DSD is one in 5,500
[7, 8]. Congenital adrenal hyperplasia (CAH) and mixed
gonadal dysgenesis (MGD) are the most common causes of
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ambiguous genitalia, constituting approximately over 50%
of all cases of genital ambiguity in the newborn period [9].
)e incidence of CAH and MGD worldwide is 1 :15,000 and
1 :10,000, respectively, but varies considerably among dif-
ferent populations [10–12].
In Kenya, there are currently no data on the frequency of
etiological diagnoses and clinical presentation of DSD in
Kenyan children and adolescents. Furthermore, diagnosis
and management of DSD in resource-limited settings like
ours represent a major challenge. Awareness among health
care workers is thought to be poor resulting in delayed
diagnosis and high morbidity and mortality.
)e aim of this study was to describe the baseline data on
etiological distribution, clinical characteristics, laboratory
evaluation, and management strategies in Kenyan children
and adolescents with DSD. Due to the challenges of con-
ducting molecular genetic analysis in our setting, the di-
agnosis of DSD in this study was based on clinical and
biochemical features. We hope that the study results will be
used to inform future policies that will enhance the quality of
care given to these patients as well as add to the body of
knowledge on DSD from this region. It will also serve as a
basis for appropriate further research.
2. Methods
We retrospectively evaluated in January and February 2016
the records of 71 consecutive patients on follow-up during
the 8-year period between January 2008 and December 2015
at the Departments of Paediatrics and Surgery at Kenyatta
National Hospital (KNH) and Gertude’s Children’s Hospital
(GCH) in Nairobi, Kenya.
)e study subjects were children who had presented at
ages 0–19 years to the above two hospitals during the 8-year
study period and were conﬁrmed to have a DSD based on
clinical, laboratory, and radiological evaluation and/or
surgical laparotomy/laparoscopy. Patients with non-
congenital (acquired) problems of late puberty were ex-
cluded from the study.
A written approval was obtained from each of the study
hospitals before collection of data in the respective hospitals.
Clinical information on age at presentation, complaints,
gender of rearing, consanguinity, family history of genital
ambiguity or fetal/infant deaths, anthropometry, assessment
of pubertal stage, presence of hyperpigmentation, hyper-
tension, associated anomalies, or dysmorphic features was
obtained from patient records and recorded on the data
collection sheet. We also obtained information on socio-
demographic data, speciﬁcally relating to age, level of ed-
ucation of both the patient, and the parent/guardian and
whether in paid employment or not (parent/guardian). We
used the Prader Scoring System and External Masculini-
zation Score (EMS) to determine the degree of external
virilization [13]. Criteria that suggested DSD included overt
genital ambiguity, apparent female genitalia with clito-
romegaly, posterior labial fusion or inguinal/labial mass,
apparent male genitalia with nonpalpable testes, micropenis,
isolated perineal or penoscrotal hypospadias, mild hypo-
spadias with undescended testis, and delayed puberty. We
obtained information from the records on the investigations
done including karyotype analysis, hormone measurements,
abdominopelvic imaging, laparotomy/laparoscopy, and bi-
opsy. We also searched for patients with Turner Syndrome
and Klinefelter Syndrome which are included in the DSD
classiﬁcation.
)e subjects who had a karyotype analysis were classiﬁed
into three etiologic groups: 46,XY DSD, 46,XX DSD, and sex
chromosome DSD. A normal baseline testosterone level
(above 1 nmol/L) or a three-fold increment in plasma tes-
tosterone after human chorionic gonadotropin (hCG)
stimulation was considered to indicate the presence of
functioning testicular tissue [13, 14]. A testosterone (T) to
dihydrotestosterone (DHT) ratio greater than 12 was ac-
cepted as suggestive of 5α-reductase deﬁciency [15]. An-
drogen insensitivity syndrome (AIS) was presumed in
individuals with a 46,XY karyotype who had normal T and
DHT response (three-fold increment) to hCG stimulation
and absence of mu¨llerian structures. )e presence of normal
female external genitalia was considered suggestive of
complete androgen insensitivity syndrome (CAIS), while the
rest were considered as presumptive partial androgen in-
sensitivity syndrome (PAIS). Gonadal regression (vanishing
testes syndrome) was presumed in patients with normal
male external genitalia, low basal (below 1 nmol/L) or no
testosterone response to hCG, and bilateral anorchia on
imaging.
A presumptive diagnosis of 21-hydroxylase deﬁciency
was made in individuals with mu¨llerian structures and el-
evated basal 17-hydroxyprogesterone (17-OHP) (above
3 nmol/L, based on in-house laboratory cutoﬀ values) [16].
Gonadal dysgenesis was presumed in patients who had
underdeveloped/absent gonads detected by imaging studies
or surgical exploration. )e diagnosis of ovotesticular DSD
was based on surgical exploration and gonadal biopsy [17].
For each individual with missing measurements at ﬁrst
presentation to the health facility such as height, weight, and
blood pressure, the missing value was replaced by the next
observed value of that variable (next observation carried
backward (NOCB)). )e maximum period for imputing the
value in the next visit was two months. Any variable that was
not available for 80% or more of the study sample was not
included in the analysis. Individual cases that had more than
80% missing data were omitted from the study (available case
analysis). We discarded two patients with records that had
more than 80% missing data, one with suspected Klinefelter
syndrome and another with suspected Turner syndrome.
Data were analyzed accordingly using Statistical Product
and Service Solutions (SPSS) version 17. Chi-squared tests
were used to compare categorical variables and proportions
across groups. Continuous variables were compared using
student’s t test and Mann–Whitney U test. A p value of less
than 0.05 was considered statistically signiﬁcant.
2.1. Ethical Consideration. )e study was conducted after
obtaining written approval from the Kenyatta National
Hospital Ethics and Research Committee and Gertrude’s
Children’s Hospital Ethical Review Board in Kenya.
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3. Results
3.1. Age. )e age at the time of diagnosis among the 71
patients varied widely from birth to 17 years. )e mean age
was 2.7 years and median age 3 months, with the majority
(51%) of the children aged 5 months and below (Figure 1).
3.2. Clinical Presentation. Majority (95.7%) of the patients
presented with symptoms of DSD at birth. )e most
common presenting symptom was ambiguous genitalia,
which was present in 66 (93.0%) patients either in isolation
or in association with other symptoms.
Six patients with ambiguous genitalia had syndromic
features/multiple congenital malformations. One of these
patients who was diagnosed with Edward syndrome had
microcephaly, a low hairline and low-set ears, and had been
exposed to prenatal progestagens due to a threatened
abortion. Another patient had hirsutism and low-set ears.
)e third patient had congenital talipes equinovarus,
tongue-tie, lip-tie, obesity, and renal malformations with
recurrent urinary tract infections. )is patient had been
exposed to aspirin throughout pregnancy for maternal
chronic hypertension. )e fourth patient presented with
anorectal malformation and congenital talipes equinovarus,
while the ﬁfth one had facial hypertrichosis, a short neck and
a small chin. One neonate who was HIV-exposed presented
with ambiguous genitalia and spina biﬁda cystica.
Two patients presented with ambiguous genitalia with
acne and development of pubic hair at 3 months and 5.5
years respectively. One patient with ambiguous genitalia had
salt-wasting crisis at presentation while another had bilateral
inguinal herniae.
3.3. Anthropometric Measurements
3.3.1. Weight and Height. )e ﬁndings of physical mea-
surements based on the Centers for Disease Control and
Prevention (CDC) growth standards showed that 25 par-
ticipants (39.7% of reported measurements) had weights for
age below − 2SD at ﬁrst visit, and 20 participants (44.4% of
reported measurements) had height/length for age below
− 2SD. Sixteen percent of these children had been born
prematurely. Over half (53%) of these patients were from the
capital city of Nairobi while the rest had been referred from
outside Nairobi.
3.3.2. Blood Pressure. Out of 16 children who had blood
pressure measurements recorded, 12 (75%) were normo-
tensive and 4 (25%) were hypertensive. Among the hyper-
tensive patients, one was syndromic with anorectal
malformation and congenital talipes equinovarus. Gonadal
dysgenesis with renal failure based on a WT1 mutation is
possible in this patient who had a 46,XY karyotype and was
yet to undergo a diagnostic laparotomy/laparoscopy. An-
other patient had sex chromosome DSD (Turner variant
48,XYYY/45,X). )is patient had been referred for a kar-
yotype and was transferred back to the referring hospital for
follow-up. One patient had a presumed disorder of
testosterone biosynthesis while another did not have the
diagnosis established due to loss to follow-up. Among the
eight patients with presumed CAH, four had blood pressure
readings documented and all were normal.
3.4. Family History and Pregnancy-Related Factors
3.4.1. Genital Ambiguity. Among 58 patients, 6 (10.3%)
reported a family history of genital ambiguity. Two of these
patients had a 46,XY karyotype and had a presumed disorder
of testosterone biosynthesis. One had a maternal cousin who
was initially female and later changed to a male while the
other had a history of hypospadias in a ﬁrst-born sibling.
One patient with 46,XX ovotesticular DSD had a history of
micropenis in an unspeciﬁed family member. A patient with
46,XX testicular DSD had a cousin with a history of un-
descended testes. Two patients who did not have an
established diagnosis had a history of micropenis in a
maternal uncle and an uncle with ambiguous genitalia,
respectively. Family history of genital ambiguity was not
known in 13 patients.
3.4.2. Infertility. Five (15.2%) patients out of 33 had a family
history of infertility. All these ﬁve patients had the history of
infertility reported in the paternal aunt.)e family history of
infertility was not known in 38 patients.
3.4.3. Fetal/Infant Loss. )ere was a family history of fetal
loss/infant deaths reported in nine (30%) out of 30 cases.
Family history of fetal/infant loss was not known in 41 cases.
One patient with CAH had a history of death in a sister at 10
months of age, with the cause of death reported as “malaria”
by the parent. Two patients with CAH did not have a history
of fetal/infant death while the remaining ﬁve had no doc-
umentation on the same.
3.4.4. Consanguinity. A history of parental consanguinity
was reported in three (12.5%) out of 24 cases. In two of these
cases, the parents were reported to be from the same clan,
while in the third case, the exact relationship of the parents
was not documented. History of parental consanguinity was
not known in 47 cases.
3.4.5. Antenatal Drug Exposure. Among 60 patients, 2
(3.3%) had been exposed to drugs during the antenatal
period. )e ﬁrst patient who was diagnosed with Edward
syndrome (47,XX, +18) had been exposed to progestagens in
the ﬁrst trimester for a threatened abortion and has been
described above. In the second case also described above, the
mother was on aspirin throughout the pregnancy for chronic
hypertension. )is child had a 46,XX karyotype. )e history
of antenatal drug exposure was not known in 11 patients.
3.5. Initial Management. Fifty patients were delivered in
hospital and nine at home. )ere was no documentation on
place of delivery for 12 patients.
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Ambiguous genitalia was initially observed by the pa-
tient’s mother in 32 cases and by a health professional in 28
cases. It was not clear from the documentation who initially
observed the genital ambiguity in nine patients.
)irty-six (50.7%) patients were reared as male while 31
(43.7%) had been raised as females. )e remaining four
patients had not been assigned a gender from birth. Among
those who had karyotypes done, 19 patients had a genotype
that was discordant with the gender of rearing (10males with
46,XX karyotype, and 9 females with 46,XY karyotype).
3.6. Diagnoses. Out of the 71 children in the sample, 39
(54.9%) had karyotype testing done (Figure 2). )e rest did
not have karyotype testing due to economic reasons. )e
median age (IQR) of children with reported karyotypes and
those without was 3.3 years (1.3–8.9) and 8.3 years (3.6–
12.1), respectively, (p � 0.021).
Based on karyotype analysis, 19 (48.7%) of karyotyped
children had 46,XY DSD and 18 (46.2%) had 46,XX DSD
(Table 1). )ere were two (5.1%) children with sex chro-
mosome DSD.
Among all the 71 patients, 10 (14.1%) had a presumed
diagnosis of ovotesticular DSD (Table 2). Out of 8 (11.3%)
cases with presumed CAH, 5 had the simple virilizing form,
2 nonclassic 21-hydroxylase deﬁciency, and 1 salt-wasting
21-hydroxylase deﬁciency. All of these patients with pre-
sumed CAH except 2 had a basal 17-OHP level ranging from
39.6 to 1050 nmol/L. One patient who had presented with
salt-wasting adrenal crisis at 1 month of age and was on
hydrocortisone and table salt at the time of testing had a 17-
OHP of 6.7 nmol/L. )e second one who had presented with
ambiguous genitalia had a 17-OHP of 3.6 nmol/L, a 46,XX
karyotype, elevated testosterone levels, and low cortisol level
based on in-house laboratory cutoﬀ values.
A presumed diagnosis of 5α-reductase deﬁciency was
made in two patients. One patient was presumed to have
PAIS, and there was none with CAIS. We were not able to
perform mutation analysis of the androgen receptor (AR)
gene. Four patients were presumed to have disorders of
testosterone biosynthesis. Two of these patients had a 46,XY
karyotype and a poor testosterone response to hCG stim-
ulation. )e third patient who was aged 14 years and 11
months had a 46,XY karyotype, undetectable basal testos-
terone (hCG test not done), and right intra-abdominal and
left inguinal testes with no M}ullerian structures on lapa-
rotomy. )e fourth patient aged 4 years and 8 months had a
46,XY karyotype, low basal testosterone (hCG test not done),
and bilateral intra-abdominal testes with no M}ullerian
structures on laparotomy.
)ere were 6 patients with 46,XY karyotype in whom it
was not established whether there was a disorder of an-
drogen action or synthesis. Five of these patients had in-
complete hCG stimulation tests while one had no
biochemical tests done.
Twenty-six (36.6%) patients did not have the etiologic
diagnosis established. Ten of these patients were lost to
follow-up. )e commonest presumed diagnosis among the
nonkaryotyped patients was CAH (15.6%) and ovotesticular
DSD (12.5%).
3.7. Investigations. Forty-nine (69%) patients had an
abdominopelvic ultrasound done while 35 (49.3%) had a
laparoscopy or laparotomy as part of the investigations.
Histology of the gonads was performed for 20 (28.2%)
patients. No patient was found to have a gonadal tumour.
Four out of the 8 patients with CAH had bone age de-
termined at presentation and 3 of these patients had ad-
vanced bone age.
3.8. Gender Assignment. )irty-nine (54.9%) patients were
ﬁnally assigned a male gender, while 16 (22.5%) were
assigned a female gender by the multidisciplinary DSD team
consisting of an endocrinologist, surgeon, psychologist,
radiologist, and social worker. )e team took into account
the supposed diagnosis and tried to match the gender as-
signment to the patient’s chromosomal and gonadal sex
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Figure 1: Age at diagnosis.
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where possible, while trying to anticipate pubertal devel-
opment and future function and fertility.
)e average age for gender assignment was 3.4 years.
)ere was no documented gender incongruence/gender
dysphoria. )irteen (18.3%) of the patients did not have a
ﬁnal gender assigned, nine of whom were lost to follow-up.
)e remaining four were still undergoing diagnostic and
psychiatric evaluation. Information was not available on the
ﬁnal gender assignment for three patients who had been
transferred back to the referring facility.
Seventeen (23.9%) of the cases had a gender reassign-
ment at ﬁnal diagnosis. Among these patients, 76.5% were
reassigned from female to male gender while 23.5% were
reassigned from male to female gender. Among those
reassigned from female to male gender, the presumed di-
agnoses included 5α-reductase deﬁciency, PAIS, mixed
gonadal dysgenesis, and unclassiﬁed disorders of androgen
synthesis or action. )ose reassigned from male to female
gender included two patients with CAH and one with 46,XX
karyotype in whom the exact etiology was not established.
Twelve of these patients were below 4 years and 5 were above
5 years (5 years, 6.5 years, 7 years 1 month, 9 years 5 months,
and 15 years 8 months) at the time of reassignment.
3.9. Medical and Surgical Treatment. Six of the patients with
CAH were on hydrocortisone while one was on predniso-
lone due to ﬁnancial constraints. )e patient with salt-
wasting CAH was also on treatment with table salt.
)ree patients with 46,XY DSD and the one with mixed
gonadal dysgenesis received topical testosterone as part
of the treatment. Twenty-four patients underwent
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Table 1: Etiological classiﬁcation among karyotyped patients (n� 39).
Main category Etiologic diagnosis N Final genderassignment
Age at ﬁnal gender assignment
(years)
Sex chromosome DSD
(n� 2)
45,XO/46,XY mixed gonadal dysgenesis 1 Male 2
45,X Turner and variants 1 Unassigned
46,XY DSD (n� 19) Disorder of androgen synthesis/action 6 Male 0.2, 0.3 (2 patients), 0.5, 1.5, and 2
Disorder of testosterone biosynthesis 4 Male 2, 4, 5, and 9
5α-Reductase deﬁciency 2 Male 0.4 and 1.5
Syndromic associations 2 Male 0.2 and 0.3
Gonadal regression 1 Male 9
Partial androgen insensitivity syndrome 1 Male 3
Not established 3 2 male, 1 unassigned 0.2 and 0.3
46,XX DSD (n� 18) Ovotesticular DSD 6 4 male 0.1, 0.8, 2, and 81 female 12
Testicular DSD 5 3 male, 2 unassigned 0.4, 1, and 3
Congenital adrenal hyperplasia 3 Female 1, 4, and 7
Ovarian dysgenesis (right) 1 Female 9
Syndromic associations 1 Female 0.3
Iatrogenic (non-CAH androgen excess in
syndromic baby) 1 Female 0.1
Not established 1 Female 2
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genitoplasty/urethroplasty while 9 patients underwent
orchidopexy. Two patients with ovotesticular DSD who were
assigned male gender underwent oophorectomy while one
with ovotesticular DSD assigned a female gender underwent
bilateral gonadectomy.
3.10. Specialists Involved in Care of Patients. A paediatric
surgeon was involved in the management of 78.9% of the
patients and a paediatric endocrinologist in 77.5% of the
cases. A psychologist/psychiatrist or counselor was involved
in the management of 23.9% of the patients. Among the 28
patients who underwent psychosocial evaluation, 20 had
psychosocial issues such as aggressive behavior, poor school
performance, anxiety, withdrawal, and eating disorder.
3.11. Follow-Up Outcome. In terms of outcome, 50.7% of
patients were still being followed up in the clinics while 36.6%
were lost to followup. Some patients (11.3%) were transferred
back to the referring facilities for follow-up, while for 1.4%, there
was inadequate documentation to determine the outcome. As
shown in Table 3, karyotyped patients weremore likely to be still
on follow-up at the clinics compared to nonkaryotyped patients
(p value<0.001).
4. Discussion
According to the 2018 Report of the Taskforce on Policy,
Legal, Institutional, and Administrative Reforms regarding
the Intersex Persons in Kenya [18], only 5% of persons with
DSD recognize themselves as intersex, while the others are
mostly confused about their exact status due to lack of
awareness and support. In terms of legal recognition and
documentation, the taskforce found that majority of persons
with DSD had birth certiﬁcates, but the recorded gender
conﬂicted with the assigned gender [18]. )e birth certiﬁ-
cates make it diﬃcult to acquire identity cards with resultant
negative social implications such as missed employment and
voting opportunities [18].
In this retrospective study of 71 youth with DSD at
Kenyatta National and Gertrude’s Children’s Hospitals in
Nairobi, the most common presumed causes of DSD were
ovotesticular DSD (14.1%) and CAH (11.3%). In contrast, in
South Africa, Ganie et al. [19] found the most common
diagnoses to be unclassiﬁed disorder of androgen synthesis
and action (53%) and ovotesticular DSD (22%). In Turkey,
Erdog˘an et al. [20] found that the most common causes of
DSDwere Turner syndrome and CAH, while Parisi et al. [21]
found CAH (14%) and AIS (10%) to be the commonest
causes of DSD in Seattle.
Although ovotesticular DSD is rare [17, 22], it is thought
to be more prevalent in South African blacks [23], partic-
ularly 46,XX ovotesticular DSD. Most cases are sporadic
with few documented cases of familial recurrence. )ere are
more than 400 cases reported worldwide [24].
In our study, 6 out of the 10 patients with presumed
ovotesticular DSD had a 46,XX karyotype while the other 4
did not have a karyotype done. Krob et al. [23] observed that
out of the 96 cases described in Africa, 96.5% showed a
46,XX karyotype.
An ovotestis was the most common gonad found in
58.8% of all gonads, while an ovary was found in 23% and a
testis in 17.7%. )is ﬁnding was similar to other studies
[22, 23, 25].
Among our patients, bilateral ovotestes, an ovotestis and
ovary, and a testis and ovary were present in 2 patients each,
while 2 patients had a right ovotestis and an absent gonad on
the left. Ganie et al. [22] found an ovotestis and ovary to be
the most common combination of gonads followed by bi-
lateral ovotestes. Gonads with testicular tissue have been
found to be more frequent on the right side of the body,
while pure ovarian tissue is more common on the left
[22, 23]. Krob et al. [23] observed that histologically, ovarian
tissue often appeared normal while testicular tissue was
described to be immature. )is is in agreement with our
ﬁndings.
In our study, 48.7% of karyotyped children had 46,XY
DSD and 46.2% had 46,XXDSD.)is is similar to ﬁndings in
Table 2: Etiological diagnosis (n� 71).
Frequency (n) Percent (%)
DSD etiology
Ovotesticular DSD 10 14.1
Congenital adrenal hyperplasia 8 11.3
Disorder of androgen synthesis/action 6 8.5
Testicular DSD 5 7.1
Disorder of testosterone biosynthesis 4 5.6
Syndromic associations 3 4.2
5α-Reductase deﬁciency 2 2.8
Ovarian dysgenesis (right) 2 2.8
Gonadal regression 1 1.4
Iatrogenic (non-CAH androgen excess in
syndromic baby) 1 1.4
Mixed gonadal dysgenesis (45,XO/46,XiYq (15)) 1 1.4
Partial androgen insensitivity syndrome 1 1.4
Turner variant (48,XYYY/45,X) 1 1.4
Not established 26 36.6
Total 71 100.0
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other studies [20, 21, 26, 27]. In contrast, in Indonesia,
Juniarto et al. [28] found 46,XY DSD to be even more
common, accounting for 63.3% of cases. Our data dem-
onstrate that the commonest presumed cause of 46,XX DSD
is ovotesticular DSD (33%) followed by testicular DSD
(27%). )is is in contrast to other studies where CAH was
found to be the most common cause of 46,XX DSD
[20, 21, 28, 29]. Our ﬁndings may be explained by genetic
diﬀerences and the low rate of consanguinity in our setting.
Two out of the 3 cases that had a history of parental con-
sanguinity had presumed 46,XX testicular DSD while 1 had
46,XX ovotesticular DSD, suggesting a familial/genetic
rather than sporadic occurrence in these cases.
Despite the fact that a large proportion of patients were
delivered in hospital, ambiguous genitalia was initially ob-
served by the patient’s mother in majority of the cases. In
addition, 16 cases were never referred to the endocrine
clinic.)ismay be becausemidwives and primary healthcare
doctors are not trained on this, and there is no national
guideline for diagnosis and management of DSD.
Ninety-ﬁve percent of our patients were identiﬁed at
early age, thus “late” presenters may have been missed or
diagnosed as late puberty. It is also possible that patients
with for instance CAIS and 17β hydroxysteroid de-
hydrogenase deﬁciency with “normal” female genitalia at
birth and later presentation of inguinal hernia with gonads
may have been missed.
)e rates of underweight and stunting were higher
among these children than the national rates according to
the Kenya Demographic and Health Survey of 2014 (11%
and 26%, respectively). Apart from one child who was on
management for severe malnutrition, it was not evident
from the records whether these children were abandoned or
neglected.
Eight (32%) out of 25 patients had laparoscopy/mini-
laparotomy ﬁndings that contradicted the abdominopelvic
ultrasound ﬁndings. Ultrasound is operator-dependent.
)erefore, when resources are limited, laparoscopy or
minilaparotomy performed by an experienced surgeon may
be a cost-eﬀective way to identify internal structures.
While patients who underwent gender reassignment
were more likely to undergo psychological evaluation, only
half of them were documented to have been evaluated by a
psychologist. In our setup, patients who need to change
gender go through assessments by the psychologist, surgeon,
and paediatric endocrinologist and, when required, have a
meeting with the family and all team members. )e family is
then followed up by the psychologist. )e Kenyan taskforce
found that persons with DSD unanimously felt that surgery
should be delayed until the child reaches puberty when the
dominant sex characteristics have manifested, and the child
should consent to the medical and surgical interventions and
have all the necessary medical diagnostic tests done before
the surgery [18]. A cautious approach to gender reassign-
ment is recommended and should always be initiated by the
patient to minimize gender dissatisfaction [30]. Skilled
specialists should evaluate the patient taking into consid-
eration biological and social factors, as well as sexual and
fertility potentials [30]. Any psychiatric comorbid disorders
should be addressed to improve compliance to hormonal
treatment [30].
Ediati et al. [31] in a case-control study assessing
emotional and behavioural problems in 118 late identiﬁed
Indonesian patients with DSD aged 6 to 41 years found that
patients who were untreated for most of their lives suﬀered
more emotional and behavioural problems. Mean de-
pression and anxiety scores have been found to be higher
compared to population norms in males with Klinefelter
syndrome and males with XY-DSD [32]. Self-esteem, body
dissatisfaction, and experiences of shame were associated
with psychiatric symptomatology in many DSD conditions
[32]. It is, therefore, important that these patients receive
timely education and counseling to improve their un-
derstanding and acceptance of the diagnosis. All parents of
newborns with suspected DSD where there has been a delay
in gender assignment and all adolescents with a newly di-
agnosed or existing DSD requiring medical or surgical at-
tention should be oﬀered clinical psychology input [14].
)irty-two (45.1%) of the 71 cases in our study did not
have a karyotype done, while 26 (36.6%) patients did not
have an etiological diagnosis established. )is ﬁnding is
higher than that reported in other series [21, 26, 29].)is was
due to ﬁnancial constraints and loss to follow-up of patients.
Investigation of DSD in Kenya is very expensive and out of
reach for many patients. In addition, molecular genetic
testing for DSD is currently not available locally, and
sending samples out of the country would still require
funding from individual patients since it is currently not
ﬁnancially supported by the government. Fifty-four percent
of the respondents interviewed by the Kenyan taskforce
described their experience in accessing healthcare as poor
due to high cost of treatment and presence of very few
specialized hospitals [18].
In conclusion, the commonest cause of DSD was ovo-
testicular DSD in contrast to western studies, which found
CAH to be more common. )ere should be at least one
multidisciplinary centre for DSD in Kenya, including a
paediatric endocrinologist, psychologist, paediatric urologist
or surgeon, and geneticist.)ere is a need to train geneticists
to be included as members of the DSD team due to patients
Table 3: Karyotyped and nonkaryotyped patients in terms of outcome.
Karyotyped Not karyotyped p value
Patient outcome (n� 71)
Still followed up 27 (69.2) 9 (28.1) <0.001
Lost to follow-up 6 (15.4) 20 (62.5)
Transferred back to referring hospital 6 (15.4) 2 (6.3)
Inadequate documentation to determine outcome 0 (0.0) 1 (3.1)
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with karyotype anomalies, to interpret ﬁndings, and to
provide genetic counseling for families. Psychological
evaluation should be carried out for all patients at diagnosis
and support given for families to improve understanding of
diagnosis and avoid stigma.
Further studies should be carried out to identify the
molecular genetic etiologies. Financial limitations make
investigation and diagnosis of DSD diﬃcult; hence, in-
vestigations should be supported by health authorities di-
rectly, through health insurance and increased
budget allocation for research. A network for detailed di-
agnostics in resource-limited countries would be highly
desirable.
)ere is a need to train health care workers/medical
students for early diagnosis. A national guideline should be
developed for diagnosis and management of DSD during
and beyond the paediatric age group, and this should be re-
evaluated and modiﬁed regularly according to emerging
evidence and available resources. Every child with DSD
should have a karyotype done.
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